Cargando…
Advances in Oligonucleotide Aptamers for NSCLC Targeting
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer worldwide, with the highest incidence in developed countries. NSCLC patients often face resistance to currently available therapies, accounting for frequent relapses and poor prognosis. Indeed, despite great recent advancement...
Autores principales: | Rotoli, Deborah, Santana-Viera, Laura, Ibba, Maria L., Esposito, Carla L., Catuogno, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504093/ https://www.ncbi.nlm.nih.gov/pubmed/32842557 http://dx.doi.org/10.3390/ijms21176075 |
Ejemplares similares
-
Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts
por: Santana-Viera, Laura, et al.
Publicado: (2020) -
Aptamer Cell-Based Selection: Overview and Advances
por: Catuogno, Silvia, et al.
Publicado: (2017) -
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
por: Catuogno, Silvia, et al.
Publicado: (2016) -
The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses
por: Ciccone, Giuseppe, et al.
Publicado: (2023) -
Identification of a novel RNA aptamer that selectively targets breast cancer exosomes
por: Esposito, Carla Lucia, et al.
Publicado: (2021)